In a significant stride towards advancing precision medicine, GlaxoSmithKline (GSK) has announced a three-year collaboration agreement with Tempus, a leader in data-driven precision medicine, to get access to Tempus’ AI-enable platform, including its library of de-identified patient data. This partnership aims to harness the power of data and artificial intelligence to accelerate research and development (R&D) in the pursuit of groundbreaking treatments.
The new collaboration follows an existing one that started in 2020 with the enrolment of patients for a clinical trial suffering from certain types of cancer. In accordance with this new agreement, GKS will be able to access Tempus’ dataset, based on the work done with over 40% of oncologists in the US. Tempus’ platform provides a rapid way of testing complex biomarker hypotheses and selecting patients who could benefit from the candidate drugs contained in the GSK’s portfolio.
GKS has already provided an initial sum of 70 million USD as initial payment for its minimum financial commitment of three years, which might be extended for two additional years.
The Power of Precision Medicine
Precision medicine represents a paradigm shift in healthcare, moving away from the one-size-fits-all approach to treatments tailored to individual patients. By leveraging advanced technologies and data analytics, precision medicine seeks to unravel the complexities of diseases, identifying specific genetic and molecular factors that influence an individual’s response to treatment. This approach holds the promise of more effective therapies with fewer side effects.
GSK’s Vision for Precision Medicine
GSK has been at the forefront of embracing precision medicine as a cornerstone of its research and development strategy. The expanded collaboration with Tempus reaffirms GSK’s commitment to leveraging cutting-edge technologies to unravel the intricate genetic and molecular underpinnings of diseases. By deepening their collaboration with Tempus, GSK aims to accelerate the pace of discovery and bring innovative therapies to patients more efficiently.
According to Tony Wood, Chief Scientific Officer of GSK, “This collaboration will provide GSK with unique insights to discover better medicines and transform drug discovery. Tempus complements the work our team is already doing at the intersection of genomics and machine learning across both early discovery and clinical trials.”
The GKS’s approach perfectly fits Tempus’, as explained by Eric Lefkofsky, Founder and CEO of Tempus: “GSK’s data-first approach to therapeutic research aligns with our own, and we believe that Tempus has the resources and capabilities to complement GSK’s dedication to data science, in a way others can’t, given the breadth and depth of our platform.”
The Future Impact
The expanded collaboration between GSK and Tempus might help reshape the landscape of drug discovery and development. By combining GSK’s expertise in pharmaceuticals with Tempus’ advanced data analytics, the collaboration aims to unlock new dimensions in precision medicine. The ultimate goal is to bring about a paradigm shift in how diseases are understood, diagnosed, and treated, leading to more effective and personalized therapies.
